原创力文档- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
- 4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
- 5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传，每下载1次， 网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
CR, complete response; PR, partial response, ORR, overall response rate * ALT, alanine aminotransferase; AST, aspartate aminotransferase; MTD, maximum tolerated dose. * DOR, duration of response ; irAE, immune-related adverse event; ORR, overall response rate; q2w, every 2 weeks; q12w, every 12 weeks; SC, subcutaneous; SD, stable disease. * * irAE, immune-related adverse events; ORR, overall response rate; PFS, progression-free survival. * ORR, overall response rate. * q2w, every 2 weeks; q3w, every 3 weeks. * ORR, overall response rate; q2w, every 2 weeks; q3w, every 3 weeks; RECIST, response evaluation criteria in solid tumors. * ALT, alanine aminotransferase; AST, aspartate aminotransferase; Gr, grade; q2w, every 2 weeks; q3w, every 3 weeks. * ADCC, antibody-dependent cell-mediated cytotoxicity; ECOG , Eastern Cooperative Oncology Group; MTD, maximum tolerated dose; PS, performance status; q3w, every 3 weeks. * ORR, overall response rate; PR, partial response; SD, stable disease * ALT, alanine aminotransferase; AST, aspartate aminotransferase; DLT, dose-limiting toxicity; MTD, maximum tolerated dose. * * CR, complete response; ECOG; Eastern Cooperative Oncology Group; GM-CSF, granulocyte-macrophage colony-stimulating factor ; HSV1, herpes simplex virus 1; ORR, overall response rate; OS, overall survival; pfu, plaque-forming unit; PR, partial response; PS, performance status; q2w, every 2 weeks; SC, subcutaneous; TFT, time to treatment failure; T-VEC, talimogene laherparepvec. * CR, complete response; DRR, durable response rate; GM-CSF, granulocyte macrophage colony-stimulating factor; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response; T-VEC, talimogene laherparepvec; TTF, time to treatment failure; T-VEC, talimogene laherparepvec. * AE, adverse event; GM-CSF, granulocyte macrophage colony-stimulating factor; T-VEC, talimogene laherparepvec. * * BID, twice daily; BRAFi, BRAF inhibitor; PO, by mouth; QD, once daily. *
文档评论（0）